About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
WASHINGTON, D.C. (September 22, 2025) — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that Kyowa Kirin joined the trade association, effective immediately. Kyowa Kirin is a global specialty pharmaceutical company committed to serving people living with rare diseases and underserved medical conditions. The company has invested in drug discovery and biotechnology innovation for more than 70 years and is currently working to engineer the next generation of antibodies and cell and gene therapies.
“Kyowa Kirin in an innovative, research-driven company dedicated to medical breakthroughs and expanding their manufacturing footprint in the U.S,” said Stephen J. Ubl, President and CEO, PhRMA. “We’re proud to welcome them to the association at a critical time for our industry. They join a growing list of companies advocating for policies that put patients first and protect innovation, new treatments and new cures.”
Kyowa Kirin’s North American headquarters are based in Princeton, New Jersey, with global headquarters based in Tokyo, Japan. The company maintains a research and discovery campus in La Jolla, California, and is building a new global biologics manufacturing facility in Sanford, North Carolina. Kyowa Kirin will support PhRMA’s advocacy to ensure the latest advances in biomedical discovery, including gene therapies, fully human monoclonal antibodies, and other medical breakthroughs, are accessible and affordable for patients.
“As a company, our approach to the research and development of novel medicines is one based on innovation and collaboration,” said Steve Schaefer, President, North America, Kyowa Kirin. “That’s why we are excited to join PhRMA and expand our collaboration with other biopharmaceutical leaders here in the United States and around the world. Our team is driven by a common purpose to develop new treatments that deliver life changing value for patients with high unmet medical need. We look forward to partnering with PhRMA to advance innovative solutions that will help ensure new treatments are available and accessible for every patient who needs them.”
Kyowa Kirin is the fifth biopharmaceutical research company to join PhRMA since 2023. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States. To learn more about how the biopharmaceutical industry is investing in America, visit innovation.org/American-investment.